Seismic Therapeutic Announces Participation at Multiple Upcoming Scientific Conferences in April and May 2024

Growing body of scientific evidence demonstrates productivity of IMPACT platform and rapidly expanding pipeline opportunity in immunology

WATERTOWN, Mass.--(BUSINESS WIRE)--Seismic Therapeutic, Inc., the machine learning immunology company, today announced that the company will participate in four upcoming scientific conferences, presenting the company’s emerging pipeline of novel therapeutics to treat rare and prevalent autoimmune diseases, as well as its proprietary IMPACT platform that applies machine learning to biologics drug discovery.

"The bolus of preclinical data we are presenting in the coming months highlights the immense potential of Seismic’s pipeline in autoimmune diseases,” said Jo Viney, PhD, Founder, President and CEO of Seismic Therapeutic. “In just two years since the company’s founding, we have internally developed two potentially best-in-class development candidates as well as a number of discovery-stage programs, and these presentations from Seismic’s expert team of scientists underscore the productivity of our IMPACT platform in drug discovery. We look forward to progressing S-1117 and S-4321 through IND-enabling studies, as we work to deliver the next-generation of novel biologics to patients suffering from a variety of autoimmune diseases.”

Details of Seismic’s presentations and poster sessions are as follows:

April 16-18 – 4th Fc-Mediated Function Summit

Presentation Title: Fine-Tuning Antibody-Based Immunotherapy Identification & Characterization of FcγRIIb Selective PD-1 Agonist Antibodies to Treat Autoimmunity & Inflammation
Date: Wednesday, April 17
Time: 3:00 p.m. ET
Section: Targeting FcyR in its Own Right – What is the Next Mutation?
Presenter: Daniela Cipolletta, PhD, Senior Director of Immunology, Seismic Therapeutic

May 3-7 – IMMUNOLOGY2024™, Annual Meeting of the American Association of Immunologists

Poster Title: Identification and Characterization of PD-1 Agonists for the Treatment of Autoimmune and Inflammatory Diseases
Date: Monday, May 6
Time: 7:00 a.m. CT
Poster #: B887
Presenter: Maria Cecilia Ramello, PhD, Senior Scientist, Seismic Therapeutic

Poster Title: Preclinical Pharmacology of S-1117, a Novel Engineered Fc-fused IgG Cleaving Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases
Date: Saturday, May 4
Time: 7:00 a.m. CT
Poster #: B859
Presenter: Ivan Mascanfroni, PhD, Senior Director of Immunology, Seismic Therapeutic

In addition to the poster presentations, Seismic management will participate in the following sessions at IMMUNOLOGY2024:

Session Title: Recent Breakthroughs and Emerging Therapeutic Strategies for Chronic Inflammatory and Fibrotic Disease
Session Presentation Title: The polypharmacology of dual cell bidirectional (DcB) agonist antibodies for treating autoimmunity
Date: Saturday, May 4
Time: 8:00 a.m. CT
Session Co-Chair & Presenter: Jo Viney, PhD, Founder, CEO and President, Seismic Therapeutic

Session Title: Therapeutic Intervention for Treating Immune Dysregulation in Inflammation and Cancer
Date: Sunday, May 5
Time: 4:30 p.m. CT
Co-Moderator: Ivan Mascanfroni, PhD, Senior Director of Immunology, Seismic Therapeutic

May 13-17 – 20^th Annual PEGS Boston Summit

Presentation Title: Dual Cell Bidirectional Antibodies for Treating Autoimmunity
Session: Variety of mechanisms using bispecific antibodies
Date: Wednesday, May 15
Time: 3:00 p.m. ET
Presenter: Jyothsna Visweswaraiah, PhD, Director of Drug Creation, Seismic Therapeutic

Poster Title: Characterization of PD1 Agonizing Dual cell Bidirectional Antibodies to Treat Autoimmune Diseases
Presenter: Rasika Harshe, M.S., Senior Associate Scientist II, Seismic Therapeutic

Poster Title: Discovery and Characterization of FcγRIIb Selective Antibodies to Enhance Checkpoint Agonism and Treat Autoimmunity.
Presenter: Ishan Sharma, M.S., Scientist, Seismic Therapeutic

Poster Title: Accelerating The Discovery Of A Pan-Igg Protease Using The IMPACT Platform
Presenter: Soumya Bengeri, M.S., Senior Associate Scientist, Seismic Therapeutic

Poster Title: Design and Screening of FcγRIIb Selective Fc Domains to Enhance Checkpoint Agonism and Treat Autoimmunity
Presenter: Samuel Perry, PhD, Senior Scientist, Seismic Therapeutic

May 21-23 – 6th Treg Directed Therapies Summit

Presentation Title: Integration of Treg Biology and Immunotherapy
Session Category: Exploring the Impact of Treg Biology on Development of Treg Directed Therapies to Drive Precise Therapeutic Interventions.
Date: Tuesday, May 21
Time: 12:00 p.m. ET
Presenter: Marisella Panduro, PhD, Principal Scientist, Seismic Therapeutic

Presentation Title: Inhibitory Receptor Targeting & Modulation of Treg Biology
Session Category: Non-Cell Based Approaches
Date: Thursday, May 23
Time: 11:30 a.m. ET
Presenter: Daniela Cipolletta, PhD, Senior Director of Immunology, Seismic Therapeutic

About Seismic Therapeutic

Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X @Seismic_Tx.